Characterization of the expression of LAT1 as a prognostic indicator and a therapeutic target in renal cell carcinoma

被引：41

作者：

Higuchi, Kosuke ^{[1
,2
]}

Sakamoto, Shinichi ^{[2
]}

Ando, Keisuke ^{[1
,2
]}

Maimaiti, Maihulan ^{[2
]}

Takeshita, Nobushige ^{[1
,2
]}

Okunushi, Kentaro ^{[1
]}

Reien, Yoshie ^{[1
]}

Imamura, Yusuke ^{[2
]}

Sazuka, Tomokazu ^{[2
]}

Nakamura, Kazuyoshi ^{[2
]}

Matsushima, Jun ^{[3
]}

Furihata, Tomomi ^{[4
]}

Ikehara, Yuzuru ^{[5
]}

Ichikawa, Tomohiko ^{[2
]}

Anzai, Naohiko ^{[1
,6
]}

机构：

[1] Chiba Univ, Grad Sch Med, Dept Pharmacol, Chiba, Japan

[2] Chiba Univ, Grad Sch Med, Dept Urol, Chiba, Japan

[3] Dokkyo Med Univ Saitama, Med Ctr, Dept Pathol, Saitama, Japan

[4] Tokyo Univ Pharm & Life Sci, Dept Clin Pharm & Expt Therapeut, Tokyo, Japan

[5] Chiba Univ, Grad Sch Med, Dept Mol Tumor Pathol, Chiba, Japan

[6] Dokkyo Med Univ, Sch Med, Dept Pharmacol & Toxicol, Mibu, Tochigi, Japan

来源：

SCIENTIFIC REPORTS | 2019年 / 9卷 / 1期

基金：

日本学术振兴会;

关键词：

ACID TRANSPORTER 1; HYPOXIC MARKERS; INHIBITORS; MTORC1; JPH203;

D O I：

10.1038/s41598-019-53397-7

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Large neutral amino acid transporter 1 (LAT1, SLC7A5) is abundantly expressed in various types of cancer, and it has been thought to assist cancer progression through its activity for uptake of neutral amino acids. However, the roles of LAT1 in renal cell carcinoma (RCC) prognosis and treatment remain uncharacterized. Therefore, we first retrospectively examined the LAT1 expression profile and its associations with clinical factors in RCC tissues (n = 92). The results of immunohistochemistry showed that most of the tissues examined (92%) had cancer-associated LAT1 expression. Furthermore, the overall survival (OS) and progression-free survival (PFS) were shorter in patients with high LAT1 expression levels than in those with low LAT1 expression levels (P = 0.018 and 0.014, respectively), and these associations were further strengthened by the results of univariate and multivariate analyses. Next, we tested the effects of JPH203, which is a selective LAT1 inhibitor, on RCC-derived Caki-1 and ACHN cells. It was found that JPH203 inhibited the growth of these cell types in a dose-dependent manner. Moreover, JPH203 clearly suppressed their migration and invasion activities. Thus, our results show that LAT1 has a great potential to become not only a prognosis biomarker but also a therapeutic target in RCC clinical settings.

引用

页数：10

共 40 条

[1]

Cella D., 2019, LANCET ONCOL, V2045, P1

[2] CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway [J].

Chen, H. ;

Zhu, D. ;

Zheng, Z. ;

Cai, Y. ;

Chen, Z. ;

Xie, W. .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (07) :939-949

[3] Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial [J].

Choueiri, Toni K. ;

Figueroa, David J. ;

Fay, Andre P. ;

Signoretti, Sabina ;

Liu, Yuan ;

Gagnon, Robert ;

Deen, Keith ;

Carpenter, Christopher ;

Benson, Peter ;

Ho, Thai H. ;

Pandite, Lini ;

de Souza, Paul ;

Powles, Thomas ;

Motzer, Robert J. .

CLINICAL CANCER RESEARCH, 2015, 21 (05) :1071-1077

[4]

Chow W. H., 2017, PREV 4 ED, V387, P961, DOI [10.1093/oso/9780190238667.003.0051, DOI 10.1093/OSO/9780190238667.003.0051]

[5] Genetic Disruption of the Multifunctional CD98/LAT1 Complex Demonstrates the Key Role of Essential Amino Acid Transport in the Control of mTORC1 and Tumor Growth [J].

Cormerais, Yann ;

Giuliano, Sandy ;

LeFloch, Renaud ;

Front, Benoit ;

Durivault, Jerome ;

Tambutte, Eric ;

Massard, Pierre-Andre ;

Rodriguez de la Ballina, Laura ;

Endou, Hitoshi ;

Wempe, Michael F. ;

Palacin, Manuel ;

Parks, Scott K. ;

Pouyssegur, Jacques .

CANCER RESEARCH, 2016, 76 (15) :4481-4492

[6] Cumulative Number of Altered Biomarkers in Mammalian Target of Rapamycin Pathway Is an Independent Predictor of Outcome in Patients With Clear Cell Renal Cell Carcinoma [J].

Darwish, Oussama M. ;

Kapur, Payal ;

Youssef, Ramy F. ;

Bagrodia, Aditya ;

Belsante, Michael ;

Alhalabi, Feras ;

Sagalowsky, Arthur I. ;

Lotan, Yair ;

Margulis, Vitaly .

UROLOGY, 2013, 81 (03) :581-586

[7] HIF2α Acts as an mTORC1 Activator through the Amino Acid Carrier SLC7A5 [J].

Elorza, Ainara ;

Soro-Arnaiz, Ines ;

Melendez-Rodriguez, Florinda ;

Rodriguez-Vaello, Victoria ;

Marsboom, Glenn ;

de Carcer, Guillermo ;

Acosta-Iborra, Barbara ;

Albacete-Albacete, Lucas ;

Ordonez, Angel ;

Serrano-Oviedo, Leticia ;

Miguel Gimenez-Bachs, Jose ;

Vara-Vega, Alicia ;

Salinas, Antonio ;

Sanchez-Prieto, Ricardo ;

Martin del Rio, Rafael ;

Sanchez-Madrid, Francisco ;

Malumbres, Marcos ;

Landazuri, Manuel O. ;

Aragones, Julian .

MOLECULAR CELL, 2012, 48 (05) :681-691

[8]

Figlin R, 2012, J UROLOGY, V188, P707, DOI 10.1016/j.juro.2012.04.108

[9] Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis [J].

Furuya, Mio ;

Horiguchi, Jun ;

Nakajima, Hiroki ;

Kanai, Yoshikatsu ;

Oyama, Tetsunari .

CANCER SCIENCE, 2012, 103 (02) :382-389

[10] Biomarkers of epithelial-mesenchymal transition in localized, surgically treated clear-cell renal cell carcinoma [J].

Gasinska, Anna ;

Jaszczynski, Janusz ;

Adamczyk, Agnieszka ;

Janecka-Widla, Anna ;

Wilk, Waclaw ;

Cichocka, Anna ;

Stelmach, Andrzej .

FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2018, 56 (04) :195-206

← 1 2 3 4 →